Plasma TAFI antigen variations in healthy subjects

Thrombosis and Haemostasis

Volumn 83, Issue 6, 2000, Pages 902-905

  Chetaille, P ^a   Alessi, M C ^a   Kouassi, D ^b   Morange, P E ^a   Juhan Vague, Iréne ^a  

^a TIMONE HOSPITAL   (France)

^b Faculty of Pharmacy   (Côte d’Ivoire)

Author keywords

Carboxypeptidase B; Healthy population; Physiological variations; TAFI

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; CAUCASIAN; FEMALE; FIBRINOLYSIS; HUMAN; MALE; NEGRO; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL;

EID: 0034131501     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613941     Document Type: Article

References (19)

1. Hendricks D, Scharpé S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
2. Campbell W, Okada H. An arginin specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxy-peptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
3. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
4. Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14777-84.
5. Bajzar L, Morser J, Neisheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
6. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14777-88.
7. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carhoxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
8. Bajzar L, Neisheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
9. Wang M, Nagashima M, Morser J. Thrombin activable fibrinolysis inhibitor in rats, rabbits and dogs. Fibrinolysis & Proteolysis 1998; 12 (suppl 1): 12.
10. Von dem Borne PAK, Bajzar L, Meijers JCM, Neisheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a Thrombin-Activatable Fibrinolysis Inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
11. Broze GJr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
12. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
13. Hudson I, De Bono DP. Levels of carboxypeptidase B (thrombin-activable fibrinolysis inhibitor: TAFIa) following thrombolysis with streptokinase. Fibrinolysis & Proteolysis 1998; 12 (Suppl 1): 12.
14. Refino CJ, Schmitt D, Pater C, Eaton D, Bunting S. A carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Blood 1998; 92: 550a.
15. Neisheim ME. TAFI. Fibrinolysis and Proteolysis 1999; 13: 72-7.
16. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
17. Mosnier LO, von der Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
18. Juhan-Vague I, Alessi MC, Raccah D, Aillaud MF, Billerey M, Ansaldi J, Philip-Joet C, Vague P. Daytime fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992; 67: 76-82.
19. Schatteman KA, Goossens FJ, Scharpé SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.